or Try an Advanced Search...

    Protein Kinase Inhibitor Stocks List

    Symbol Grade Name % Change
    AVBP F ArriVent BioPharma, Inc. 1.04
    BBIO F BridgeBio Pharma, Inc. -2.28
    EXEL F Exelixis, Inc. 0.59
    NTBL F Notable Labs, Ltd. -2.14
    ALLR F Allarity Therapeutics, Inc. -14.54
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Cancer Tyrosine Kinase Cancer Treatment Orphan Drug Treatment Of Cancer Achondroplasia Acute Myeloid Leukemia Amyloid Amyloidosis Antineoplastic Drugs Bemcentinib Biopharmaceutical Biotechnology Cancer Therapies Cardiomyopathy Chronic Myeloid Leukemia Clinical Development Congenital Adrenal Hyperplasia Cyclopropanes Daiichi Sankyo

    Related ETFs - A few ETFs which own one or more of the above listed Protein Kinase Inhibitor stocks.

    Symbol Grade Name Weight
    CNCR D Loncar Cancer Immunotherapy ETF 9.24
    BBP C BioShares Biotechnology Products Fund 5.7
    IDNA C iShares Genomics Immunology and Healthcare ETF 5.19
    SBIO D ALPS Medical Breakthroughs ETF 4.12
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 3.69
    View all Protein Kinase Inhibitor ETFs...
    Compare ETFs
    Compare BBP to LABD Compare CNCR to BBP Compare IDNA to SBIO

        Protein Kinase Inhibitor Stocks Recent News

        Date Stock Title
        May 7 ALLR Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
        May 6 EXEL Exelixis (EXEL) International Revenue Performance Explored
        May 6 ALLR Allarity exceeds Nasdaq's minimum equity requirement
        May 6 ALLR Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
        May 4 BBIO What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today
        May 3 BBIO BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations
        May 3 BBIO BridgeBio Oncology Therapeutics launches with $200m funding
        May 2 EXEL Exelixis, Inc. (NASDAQ:EXEL) Q1 2024 Earnings Call Transcript
        May 2 EXEL Exelixis: With Patent Litigation Decision Due Soon, There Are Options
        May 2 EXEL Exelixis, Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
        May 2 ALLR Allarity rallies on conclusion of mid-stage trial for its ovarian cancer treatment after showing clinical benefit
        May 2 ALLR Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
        May 2 BBIO BridgeBio Pharma GAAP EPS of -$0.20 beats by $0.31, revenue of $211.12M beats by $127.34M
        May 2 BBIO BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
        May 2 BBIO BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
        May 2 BBIO BridgeBio spinout launches with $200M for KRAS cancer drugs
        May 1 EXEL Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
        May 1 BBIO Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life
        May 1 EXEL Q1 2024 Exelixis Inc Earnings Call
        May 1 EXEL Exelixis Inc (EXEL) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ...
        Related Industries: Biotechnology
        Related Stock Lists: Cancer Biopharmaceutical Tyrosine Kinase Receptors Biotechnology Breast Cancer Drugs Gastrointestinal Gastrointestinal Stromal Tumor Her2 Mastocytosis Solid Tumors Systemic Mastocytosis Treatment Of Breast Cancer Tyrosine Kinase Blastoma Clinical Medicine Enzymes Gastrointestinal Stromal Tumors Glioblastoma Glioblastoma Multiforme
        Protein Kinase Inhibitor

        Protein kinase inhibitors are drugs that block the activity of one or more protein kinases. Protein kinases are enzymes that add phosphate groups to proteins, which can alter their activity and function. Protein kinase inhibitors are used to treat a variety of diseases, including cancer, inflammation, and autoimmune disorders.

        Browse All Tags